|
|
 | | | |
- close
- close
- close
- close
Cypress Bioscience (CYPB) |
FierceBiotech
Jan 21
Comment
New York investors have completed their acquisition of San Diego drugmaker Cypress Bioscience, which had been a publicly held company, a spokesman for the new owners said Thursday. The acquisition by the hedge fund Ramius and drug company Royalty...
Marketwire
Jan 4
Comment
SAN DIEGO, CA and NEW YORK, NY -- (Marketwire) -- 01/04/11 -- Cypress Bioscience, Inc. (NASDAQ: CYPB) ("Cypress"), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system disorders, today announced that
StreetInsider.com
Dec 21
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Ramius+Extends+Tender+Offer+Expiration+on+Cypress+Bioscience+%28CYPB%29/6175995.html for the full story.
MarketWatch
Dec 15
Comment
Cypress Bioscience shares jumped 12% to $6.47 early Wednesday on news that it has agreed to be acquired by Ramius V&O Acquisition LLC and Royalty Pharma for $6.50 a share, or $255 million. Ramius, which already owns shares of Cypress, said the...
Globe Newswire
Dec 15
Comment
NEW YORK, Dec. 15, 2010 (GLOBE NEWSWIRE) -- Arcadia Capital Advisors, LLC ("Arcadia"), a shareholder of Cypress Bioscience, Inc. ("Cypress", or the "Company"), and its managing director, Richard S. Rofe ("Rofe") have released a letter to shareholders
Stock Blog Hub
Nov 26
Comment
Cypress Bioscience, Inc. (CYPB) reported a net loss of 94 cents per share in the third quarter, significantly higher than the Zacks Consensus Estimate of a loss of 33 cents and the year ago loss of 12 cents. Despite an increase in revenues, higher...
StreetInsider.com
Nov 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Cypress+Bioscience+%28CYPB%29+Posts+Mixed+Q3+Results/6088019.html for the full story.
Marketwire
Nov 9
Comment
SAN DIEGO, CA -- (Marketwire) -- 11/09/10 -- Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced financial results for the third quarter of 2010. The Company reported total revenue of $8.0 million for the quarter ended September 30, 2010, which
Benzinga
Oct 11
Comment
Ramius Value and Opportunity Advisors LLC, a subsidiary of Ramius LLC today announced that it is extending its previously announced tender offer for all outstanding shares of common stock of Cypress Bioscience, Inc. (Nasdaq: CYPB) until 12:00...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
